Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial

Follows Earlier Positive Phase I Clinal Data For Biosimilar Rival To Lantus

21 Oct 2021

Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).

Diabetes; Chalkboard on a wooden background — Gan & Lee And Sandoz Have Been Partners Since Late 2018 • Source: Alamy

Sandoz’ global partnership with Gan & Lee Pharmaceuticals has passed another milestone, with the Chinese firm announcing the completion of two randomized, multi-center, Phase III clinical studies comparing its proposed GL-GLA biosimilar insulin glargine biosimilar to the reference biologic, Sanofi’s Lantus.

“The primary purpose of these 26-week studies” – one in subjects with type 1 diabetes and the other in subjects...